Ocular Therapeutix (OCUL) Tops Q3 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $15.08 million versus the consensus estimate of $15.23 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits